Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.

ABSTRACT:

Background

Biomarkers such as amyloid imaging are increasingly used for diagnosis in the early stages of Alzheimer's disease. Very few studies have examined this from the perspective of the patient. To date, there is only limited evidence about how patients experience and value disclosure in an early disease stage.

Methods

Semistructured interviews were carried out with 38 patients with amnestic mild cognitive impairment as part of an investigator-driven diagnostic trial (EudraCT, 2013-004671-12; registered on 20 June 2014) in which participants could opt to know the binary outcome (positive/negative) result of their amyloid positron emission tomography (PET) scan. Verbatim transcripts of the interviews were evaluated using qualitative content analysis and NVivo 11 software.

SUBMITTER: Vanderschaeghe G 

PROVIDER: S-EPMC5712105 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature